7 suspended. 7 Phase 2, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Suspended 7 |
| Phase 3 | 4 | Suspended 4 |
Follow Pneumonia: new trials by email Literature Review of Pneumonia trials Research Report on Pneumonia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults in Turkey Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated, High-dose COVID-19 Vaccine(Vero Cell),Inactivated - COVID-19 | Phase 2 | Suspended | Sinovac Research and Development Co., Ltd. | 640 | 2022-12-15 | 2022-08-11 |
| Yinhu Qingwen Granula for the Treatment of Severe CoVID-19 Yinhu Qingwen Granula, Yin Hu Qing Wen Granula(low does), standard medical treatment - COVID-19, Severe Pneumonia | Phase 2 / Phase 3 | Suspended | Zhong Wang | 116 | 2021-11-01 | 2021-07-07 |
| Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19 YinHu QingWen Decoction, YinHu QingWen Decoction(low dose), Chinese medicine treatment - CoVID-19, Chinese Medicine | Phase 2 / Phase 3 | Suspended | China Academy of Chinese Medical Sciences | 300 | 2021-10-01 | 2021-07-07 |
| Safety, Tolerability and Efficacy Of S-1226 in Moderate Severity Covid-19 Bronchiolitis/Pneumonia S-1226 - Covid19, SARS-CoV-2 Infection | Phase 2 | Suspended | SolAeroMed Inc. | 30 | 2021-09-15 | 2021-08-23 |
| CBD Oil for Reducing Emotional Impact of COVID-19 CBD Isolate, Full Spectrum CBD Oil, Broad-Spectrum CBD Oil - Anxiety Depression, Alcohol Abuse | Phase 2 / Phase 3 | Suspended | University of Texas at Austin | 200 | 2020-12-04 | 2023-11-22 |
| Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial Decitabine, Placebo Saline - COVID-19 | Phase 2 | Suspended | Johns Hopkins University | 33 | 2020-09-14 | 2025-08-29 |
| Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO Sarilumab, Azithromycin, Hydroxychloroquine - COVID19, SARS-CoV-2 Infection | Phase 2 / Phase 3 | Suspended | Assistance Publique - Hôpitaux de Paris | 27 | 2020-04-11 | 2020-05-06 |
COVID-19 (7) · Alcoholism (1) · Fractures, Stress (1) · Parasomnias (1) · Substance-Related Disorders (1)
Coronaviridae Infections (7) · Coronavirus Infections (7) · Infections (7) · Lung Diseases (7) · Nidovirales Infections (7) · Pneumonia, Viral (7) · RNA Virus Infections (7) · Respiratory Tract Diseases (7) · Respiratory Tract Infections (7) · Virus Diseases (7) · Alcohol-Related Disorders (1) · Chemically-Induced Disorders (1) · Fractures, Bone (1) · Mental Disorders (1)
Azithromycin (1) · Decitabine (1) · Hydroxychloroquine (1) · perfluorooctylbromide and CO2 drug combination (1) · sarilumab (1) · sinovac COVID-19 vaccine (1)
Assistance Publique - Hôpitaux de Paris (1) · China Academy of Chinese Medical Sciences (1) · Johns Hopkins University (1) · Sinovac Research and Development Co., Ltd. (1) · SolAeroMed Inc. (1) · University of Texas at Austin (1) · Zhong Wang (1)
China (2) · United States (2) · Canada (1) · France (1) · Turkey (Türkiye) (1)
Jiang-Rong Huang, M.D. (2) · Xiao-Dong Li, M.D. (2) · Dong Shang, M.D. (1) · Mark Montgomery, MD (1) · Michael J Telch, Ph.D. (1) · Pali Shah, M.D (1) · Wei Zhang (1) · Zhong Wang, M.D. (1)